CRISPR THERAPEUTICS AG Investing Cash Flow
CRISPR THERAPEUTICS AG (CRSP) reported Investing Cash Flow of -$466.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-03
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$55.66M, a 179.54% decline year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$410.74M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $37.20M, a 64.85% decline year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$119.23M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for fiscal 2025 was -$31.80M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for fiscal 2024 was -$280.48M, a 174.87% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for fiscal 2023 was $374.65M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities for fiscal 2022 was -$258.65M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$55.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$466.40M 10-Q · filed 2026-08-03 | -$429.20M derived: sum of 3 quarters · filed 2026-08-03 | -$548.43M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$410.74M 10-Q · filed 2026-05-04 | -$373.54M derived: sum of 2 quarters · filed 2026-05-04 | -$492.77M derived: sum of 3 quarters · filed 2026-05-04 | -$422.79M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $37.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$82.03M derived: sum of 2 quarters · filed 2026-02-12 | -$12.05M derived: sum of 3 quarters · filed 2026-08-03 | -$31.80M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$119.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$49.25M derived: sum of 2 quarters · filed 2026-08-03 | -$69.00M 10-Q · filed 2025-11-10 | $36.82M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $69.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $50.22M 10-Q · filed 2026-08-03 | $156.05M derived: sum of 3 quarters · filed 2026-08-03 | -$5.55M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$19.75M 10-Q · filed 2026-05-04 | $86.07M derived: sum of 2 quarters · filed 2026-05-04 | -$75.53M derived: sum of 3 quarters · filed 2026-05-04 | -$202.44M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $105.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$55.78M derived: sum of 2 quarters · filed 2026-02-12 | -$182.68M derived: sum of 3 quarters · filed 2026-02-12 | -$280.48M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$161.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$288.51M derived: sum of 2 quarters · filed 2025-11-10 | -$386.31M 10-Q · filed 2025-11-10 | -$467.76M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$126.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$224.71M 10-Q · filed 2025-08-04 | -$306.16M derived: sum of 3 quarters · filed 2026-02-12 | -$184.81M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$97.80M 10-Q · filed 2025-05-06 | -$179.25M derived: sum of 2 quarters · filed 2026-02-12 | -$57.91M derived: sum of 3 quarters · filed 2026-02-12 | $159.02M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$81.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $39.90M derived: sum of 2 quarters · filed 2026-02-12 | $256.82M derived: sum of 3 quarters · filed 2026-02-12 | $374.65M 10-K · filed 2026-02-12 |
| 2023-09-30 | $121.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $338.27M derived: sum of 2 quarters · filed 2024-11-05 | $456.10M 10-Q · filed 2024-11-05 | $280.57M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $216.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $334.75M 10-Q · filed 2024-08-05 | $159.22M derived: sum of 3 quarters · filed 2025-02-11 | $246.68M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $117.83M 10-Q · filed 2024-05-08 | -$57.70M derived: sum of 2 quarters · filed 2025-02-11 | $29.76M derived: sum of 3 quarters · filed 2025-02-11 | -$26.31M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$175.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$88.07M derived: sum of 2 quarters · filed 2025-02-11 | -$144.14M derived: sum of 3 quarters · filed 2025-02-11 | -$258.65M 10-K · filed 2025-02-11 |
| 2022-09-30 | $87.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $31.39M derived: sum of 2 quarters · filed 2023-11-06 | -$83.12M 10-Q · filed 2023-11-06 | -$91.84M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$56.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$170.59M 10-Q · filed 2023-08-07 | -$179.30M derived: sum of 3 quarters · filed 2024-02-21 | -$744.48M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$114.52M 10-Q · filed 2022-05-09 | -$123.23M derived: sum of 2 quarters · filed 2024-02-21 | -$688.41M derived: sum of 3 quarters · filed 2024-02-21 | -$982.05M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$573.90M derived: sum of 2 quarters · filed 2024-02-21 | -$867.53M derived: sum of 3 quarters · filed 2024-02-21 | -$1.04B 10-K · filed 2024-02-21 |
| 2021-09-30 | -$565.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$858.82M derived: sum of 2 quarters · filed 2022-11-01 | -$1.03B 10-Q · filed 2022-11-01 | -$1.23B derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$293.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$461.53M 10-Q · filed 2022-08-08 | -$665.78M derived: sum of 3 quarters · filed 2023-02-21 | -$996.11M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$167.90M 10-Q · filed 2022-05-09 | -$372.14M derived: sum of 2 quarters · filed 2023-02-21 | -$702.47M derived: sum of 3 quarters · filed 2023-02-21 | -$706.08M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$204.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$534.57M derived: sum of 2 quarters · filed 2023-02-21 | -$538.18M derived: sum of 3 quarters · filed 2023-02-21 | -$541.17M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$330.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$333.94M derived: sum of 2 quarters · filed 2021-11-03 | -$336.93M 10-Q · filed 2021-11-03 | -$329.87M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$6.60M 10-Q · filed 2021-07-29 | $461.00K derived: sum of 3 quarters · filed 2022-02-15 | -$2.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$2.99M 10-Q · filed 2021-04-27 | $4.07M derived: sum of 2 quarters · filed 2022-02-15 | $1.60M derived: sum of 3 quarters · filed 2022-02-15 | -$569.00K derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $4.60M derived: sum of 2 quarters · filed 2022-02-15 | $2.42M derived: sum of 3 quarters · filed 2022-02-15 | $1.32M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | -$4.63M derived: sum of 2 quarters · filed 2020-10-28 | -$5.73M 10-Q · filed 2020-10-28 | -$6.73M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | -$3.27M 10-Q · filed 2020-07-27 | -$4.27M derived: sum of 3 quarters · filed 2021-02-16 | -$4.97M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | -$1.10M 10-Q · filed 2020-04-28 | -$2.10M derived: sum of 2 quarters · filed 2021-02-16 | -$2.79M derived: sum of 3 quarters · filed 2021-02-16 | -$3.31M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | -$1.70M derived: sum of 2 quarters · filed 2021-02-16 | -$2.22M derived: sum of 3 quarters · filed 2021-02-16 | -$2.77M 10-K · filed 2021-02-16 |
| 2018-09-30 | -$695.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | -$1.22M derived: sum of 2 quarters · filed 2019-10-28 | -$1.77M 10-Q · filed 2019-10-28 | -$1.98M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | -$523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$1.08M 10-Q · filed 2019-07-29 | -$1.28M derived: sum of 3 quarters · filed 2020-02-12 | -$4.78M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | -$555.00K 10-Q · filed 2019-04-29 | -$760.00K derived: sum of 2 quarters · filed 2020-02-12 | -$4.25M derived: sum of 3 quarters · filed 2020-02-12 | |
| 2017-12-31 | -$205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$3.70M derived: sum of 2 quarters · filed 2020-02-12 | -$8.31M 10-K · filed 2020-02-12 | |
| 2017-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$8.11M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$4.62M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $31.88M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |